Stock Analysts’ Updated EPS Estimates for August, 11th (ADRNY, AEO, AKTX, APRN, AZPN, BRK.B, CONE, HSGX, JACK, JCP)

Stock Analysts’ updated eps estimates for Friday, August 11th:

Ahold NV (OTCMKTS:ADRNY) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Koninklijke Ahold Delhaize N.V. provides retail stores which offer food and non-food products primarily in the United States and Europe. The Company operates supermarkets, convenience stores, compact hypers, pick-up points and gasoline stations as well as specialty stores. Koninklijke Ahold Delhaize N.V., formerly known as Ahold N.V., is based in Zaandam, Netherlands. “

American Eagle Outfitters (NYSE:AEO) had its hold rating reaffirmed by analysts at Deutsche Bank AG. The firm currently has a $12.00 target price on the stock, down from their previous target price of $13.00.

Akari Therapeutics PLC (NASDAQ:AKTX) had its neutral rating reissued by analysts at Chardan Capital. The firm currently has a $2.50 target price on the stock, down from their previous target price of $6.00.

Blue Apron Holdings (NASDAQ:APRN) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $6.50 target price on the stock, down from their previous target price of $10.00.

Aspen Technology (NASDAQ:AZPN) had its hold rating reiterated by analysts at Canaccord Genuity.

Berkshire Hathaway (NYSE:BRK.B) had its price target boosted by Barclays PLC from $191.00 to $205.00. The firm currently has an overweight rating on the stock.

CyrusOne (NASDAQ:CONE) had its buy rating reiterated by analysts at Deutsche Bank AG. They currently have a $64.00 price target on the stock, up from their previous price target of $62.00.

Histogenics Corporation (NASDAQ:HSGX) had its buy rating reiterated by analysts at Canaccord Genuity. The firm currently has a $4.00 target price on the stock. The analysts wrote, “We highlight that momentum in patient enrollment accelerated in the Q2 with a record of 17 patients enrolled in the month of June and a total of 30 in the quarter. Furthermore, the company reiterated its expectations to deliver one-year data by the end of Q3/18, supporting its BLA filing shortly thereafter, and commercial launch of NeoCart as early as mid-2019. In Japan, management highlighted an agreement with the Japan PMDA regarding a regulatory pathway for the Japanese market, which will revolve around a small, 30- patient, one-year trial comparing NeoCart to microfracture treatment. The trial will be supplemented by US Phase 3 trial data, and Histogenics is currently exploring Japanese partnership opportunities to support the trial with hopes of finagling a partnership by YE/17. Of note, Histogenics hopes its Japanese partnership will provide the company with additional capital. We are encouraged by the progress in Japan and anticipate the geography could be a meaningful market for Histogenics’ long-term success. Investment highlights Reiterated expectations to deliver one-year NeoCart Phase 3 data by the end of Q3/18, supporting BLA filing shortly thereafter, and commercial launch of NeoCart in H2/19. Strengthened commercial management team with the appointment of Donald Haut, PhD as chief business officer. Dr.””

Jack In The Box (NASDAQ:JACK) had its neutral rating reissued by analysts at Cowen and Company. Cowen and Company currently has a $99.00 target price on the stock, down from their previous target price of $105.00.

J.C. Penney Company, Inc. Holding (NYSE:JCP) was given a $4.00 price target by analysts at Piper Jaffray Companies. The firm currently has a hold rating on the stock.

Nordstrom (NYSE:JWN) had its target price raised by Wolfe Research from $45.00 to $47.00. Wolfe Research currently has an outperform rating on the stock.

Kimberly-Clark Corporation (NYSE:KMB) was given a $131.00 price target by analysts at Citigroup Inc.. The firm currently has a hold rating on the stock.

Legg Mason (NYSE:LM) had its hold rating reaffirmed by analysts at Citigroup Inc.. The firm currently has a $41.00 target price on the stock.

Macy’s (NYSE:M) had its market perform rating reaffirmed by analysts at Cowen and Company. Cowen and Company currently has a $23.00 target price on the stock, down from their previous target price of $26.00.

NovaBay Pharmaceuticals (NYSE:NBY) had its hold rating reissued by analysts at Maxim Group.

Netflix (NASDAQ:NFLX) had its buy rating reissued by analysts at Cantor Fitzgerald. The firm currently has a $205.00 price target on the stock. The analysts wrote, “The Walt Disney Company (DIS: NC)) announced that it would launch a Disney-branded direct-to-consumer streaming service in 2019 (and an ESPN sports streaming service in early 2018).””

NVIDIA Corporation (NASDAQ:NVDA) had its outperform rating reissued by analysts at Royal Bank Of Canada. The firm currently has a $175.00 price target on the stock.

NVIDIA Corporation (NASDAQ:NVDA) had its buy rating reissued by analysts at Mizuho. Mizuho currently has a $180.00 price target on the stock, up from their previous price target of $170.00.

NVIDIA Corporation (NASDAQ:NVDA) had its underperform rating reissued by analysts at Wells Fargo & Company. Wells Fargo & Company currently has a $75.00 target price on the stock.

QTS Realty Trust (NYSE:QTS) had its hold rating reissued by analysts at Deutsche Bank AG. The firm currently has a $52.00 price target on the stock, down from their previous price target of $53.00.

Shire PLC (NASDAQ:SHPG) was downgraded by analysts at Barclays PLC from an overweight rating to an equal weight rating.

Snap (NYSE:SNAP) had its sell rating reiterated by analysts at Summit Redstone. They currently have a $8.00 price target on the stock, down from their previous price target of $10.00.

Snap (NYSE:SNAP) had its hold rating reissued by analysts at Canaccord Genuity. The firm currently has a $15.00 target price on the stock, down from their previous target price of $22.00.

Snap (NYSE:SNAP) had its buy rating reiterated by analysts at Goldman Sachs Group, Inc. (The). Goldman Sachs Group, Inc. (The) currently has a $23.00 target price on the stock, down from their previous target price of $27.00.

Snap (NYSE:SNAP) had its neutral rating reaffirmed by analysts at Piper Jaffray Companies. Piper Jaffray Companies currently has a $12.50 target price on the stock, down from their previous target price of $16.50.

Syndax Pharmaceuticals (NASDAQ:SNDX) was given a $20.00 price target by analysts at Citigroup Inc.. The firm currently has a buy rating on the stock.

Sidoti started coverage on shares of Thor Industries (NYSE:THO). The firm issued a buy rating and a $133.00 price target on the stock.

Urban Outfitters (NASDAQ:URBN) had its hold rating reiterated by analysts at Deutsche Bank AG. Deutsche Bank AG currently has a $18.00 price target on the stock, down from their previous price target of $19.00.

The ExOne (NASDAQ:XONE) had its hold rating reaffirmed by analysts at Canaccord Genuity. The firm currently has a $11.00 price target on the stock.